Aeolus Pharmaceuticals Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2013. For the quarter, the company's contract revenue was $844,000 against $1,448,000 a year ago. Loss from operations was $786,000 against $602,000 a year ago. Net loss was $786,000 or $0.01 per basic and diluted share against net income of $3,064,000 or $0.02 per basic share a year ago.

For the nine months, the company's contract revenue was $3,045,000 against $5,894,000 a year ago. Loss from operations was $2,031,000 against $1,874,000 a year ago. Net loss was $2,541,000 or $0.03 per basic and diluted share against net income of $8,804,000 or $0.02 per diluted share a year ago. Net cash used in operating activities was $1,107,000 against $953,000 a year ago.